DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Prenatal & Maternal Diagnostic Market Analysis to 2021" report to their offering.
The global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today
This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%.
The new report, entitled GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS to 2021 indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021. This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis.
When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and preimplantation genetic diagnosis (PGD) tests (prior to in vitro fertilization).
In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cffDNA from maternal blood.
Key Topics Covered:
1.0 Introduction
2.0 Prenatal Pregnancy Complications: An Overview
3.0 Types of Genetic Diseases in Fetuses: An Overview
4.0 Genetic Counseling: An Overview
5.0 Prenatal Screening for Genetic Diseases: An Overview
6.0 Newborn Screening
7.0 Preconception/Carrier Screening
8.0 Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview
9.0 Market Analysis
10.0 Other Genetic Testing-Related Markets
11.0 Market SWOT and Strategy Analysis
12.0 Company Profiles
- 23andMe Inc.
- Abbott Laboratories
- gnostics Inc.
- Ansh Labs
- Appistry Inc.
- ARUP Laboratories
- AssureRx Health Inc.
- Asuragen Inc.
- Berry Genomics Co., Ltd.
- Bina Technologies Inc.
- Claritas Genomics Inc.
- CLC bio A/S
- Combimatrix Corp.
- Contec Medical Systems Co., Ltd.
- Coriell Life Sciences Inc.
- Eurofins MWG Operon Inc.
- Exiqon A/S
- Genway Biotech Inc.
- Good Start Genetics Inc.
- Hitachi Medical Systems America Inc.
- Hologic Inc.
- Illumina Inc.
- INEX Innovations Exchange Pte., Ltd.
- Invitae Corp.
- Laboratory Corporation of America Inc.
- Pathway Genomics Corp.
- PerkinElmer Life and Analytical Sciences Inc.
- Premaitha Health PLC
- Progenity Inc.
- Recombine Inc.
- Reproductive Genetics Institute Inc.
- Stra Biotech GmbH
- Sygnis AG
- SynapDx Corp.
- Thermo Fisher Scientific Inc.
For more information about this report visit http://www.researchandmarkets.com/research/rhf3x3/global_prenatal
Related Topics: Diagnostics, Women's Health
